A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors

NCT07509684 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: ALK-N001 for Injection

Sponsor

Zhejiang Anglikang Pharmaceutical Co., Ltd.